Literature DB >> 20391482

Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis.

B J Radovits1, J Fransen, S Al Shamma, A M Eijsbouts, P L C M van Riel, R F J M Laan.   

Abstract

OBJECTIVE: To investigate mortality rates, causes of death, time trends in mortality, prognostic factors for mortality, and the relationship between disease activity and mortality over a 23-year period in an inception cohort of rheumatoid arthritis (RA) patients.
METHODS: A prospective inception cohort of RA patients diagnosed between January 1985 and October 2007 was followed for up to 23 years after diagnosis. Excess mortality was analyzed by comparing the observed mortality in the RA cohort with the expected mortality based on the general population of The Netherlands, matched for age, sex, and calendar year. Period analysis was used to examine time trends in survival across calendar time. Prognostic factors for mortality and the influence of the time-varying Disease Activity Score in 28 joints (DAS28) on mortality were analyzed using multivariable Cox proportional hazards models. Causes of death were analyzed.
RESULTS: Of the 1,049 patients in the cohort, 207 patients died. Differences in observed and expected mortality emerged after 10 years of followup. No improvement in survival was noted over calendar time. Significant baseline predictors of survival were sex, age, rheumatoid factor, disability, and comorbidity. Higher levels of DAS28 over time, adjusted for age, were associated with lower survival rates, more so in men (hazard ratio [HR] 1.58, 95% confidence interval [95% CI] 1.35-1.85) than in women (HR 1.21, 95% CI 1.04-1.42).
CONCLUSION: Excess mortality in RA emerged after 10 years of disease duration. Absolute survival rates have not improved in the last 23 years and a trend toward a widening mortality gap between RA patients and the general population was visible. Higher disease activity levels contribute to premature death in RA patients.

Entities:  

Mesh:

Year:  2010        PMID: 20391482     DOI: 10.1002/acr.20105

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  38 in total

Review 1.  Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality.

Authors:  Elena Myasoedova; John M Davis; Cynthia S Crowson; Sherine E Gabriel
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

2.  [The safety of biologics : a risk-benefit assessment of treating rheumatoid arthritis with biologics based on registry data on mortality].

Authors:  O Sander
Journal:  Z Rheumatol       Date:  2010-11       Impact factor: 1.372

Review 3.  Advances in the medical treatment of rheumatoid arthritis.

Authors:  J Michelle Kahlenberg; David A Fox
Journal:  Hand Clin       Date:  2011-02       Impact factor: 1.907

4.  Rheumatoid Arthritis and Mortality Among Women During 36 Years of Prospective Follow-Up: Results From the Nurses' Health Study.

Authors:  Jeffrey A Sparks; Shun-Chiao Chang; Katherine P Liao; Bing Lu; Alexander R Fine; Daniel H Solomon; Karen H Costenbader; Elizabeth W Karlson
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-06       Impact factor: 4.794

Review 5.  Treatment failure in inflammatory arthritis: time to think about syndemics?

Authors:  Elena Nikiphorou; Heidi Lempp; Brandon A Kohrt
Journal:  Rheumatology (Oxford)       Date:  2019-09-01       Impact factor: 7.580

6.  Development of Cardiovascular Quality Indicators for Rheumatoid Arthritis: Results from an International Expert Panel Using a Novel Online Process.

Authors:  Claire E H Barber; Deborah A Marshall; Nanette Alvarez; G B John Mancini; Diane Lacaille; Stephanie Keeling; J Antonio Aviña-Zubieta; Dmitry Khodyakov; Cheryl Barnabe; Peter Faris; Alexa Smith; Raheem Noormohamed; Glen Hazlewood; Liam O Martin; John M Esdaile
Journal:  J Rheumatol       Date:  2015-07-15       Impact factor: 4.666

7.  Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap.

Authors:  Diane Lacaille; J Antonio Avina-Zubieta; Eric C Sayre; Michal Abrahamowicz
Journal:  Ann Rheum Dis       Date:  2016-12-28       Impact factor: 19.103

8.  A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis.

Authors:  Devin Incerti; Jeffrey R Curtis; Jason Shafrin; Darius N Lakdawalla; Jeroen P Jansen
Journal:  Pharmacoeconomics       Date:  2019-06       Impact factor: 4.981

9.  Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment.

Authors:  Maria Rehnberg; Mikael Brisslert; Sylvie Amu; Kiandoht Zendjanchi; Gunilla Håwi; Maria I Bokarewa
Journal:  Arthritis Res Ther       Date:  2010-06-08       Impact factor: 5.156

10.  Determinants of mortality among postmenopausal women in the women's health initiative who report rheumatoid arthritis.

Authors:  Lewis H Kuller; Rachel H Mackey; Brian T Walitt; Kevin D Deane; V Michael Holers; William H Robinson; Jeremy Sokolove; Yuefang Chang; Simin Liu; Christine G Parks; Nicole C Wright; Larry W Moreland
Journal:  Arthritis Rheumatol       Date:  2014-03       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.